Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fabian Hansen
AddedMar 31, 2024
UpdatedMay 31, 2026
Fabian Hansen

Fabian Hansen

Co-Founder, Presight Capital

CrunchbaseLinkedIn

Fabian Hansen's Career

Presight Capital
Presight Capital

West Hollywood, CA, US

Co-Founder
Angiex
Angiex

Cambridge, MA, US

Board Member· Board
Peptilogics
Peptilogics

Pittsburgh, PA, US

Board Member· Board
Alloy Therapeutics
Alloy Therapeutics

Waltham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fabian Hansen's Career

Presight Capital
Presight Capital
Investment FirmInvestment Firm52019West Hollywood, CA, US
Co-Founder

Leadership at Presight Capital

Christian AngermayerChristian AngermayerCo-Founder

Similar to Presight Capital

Foresite CapitalForesite CapitalSan Francisco, CA, USest. 2011Foresite CapitalSan Francisco, CA, US · est. 2011

Foresite Capital: A leading US venture capital & growth equity firm, headquartered in San Francisco.

Investment Firm68
Preface VenturesPreface VenturesNew York City, NY, USest. 2021Preface VenturesNew York City, NY, US · est. 2021

Preface Ventures: A full-service investment firm, partnering with Frontier Enterprises, investing $500k-$1M in pre/seed rounds.

Investment Firm9
Start CapitalStart CapitalLondon, Greater London, GBest. 2010Start CapitalLondon, Greater London, GB · est. 2010

Start Capital: A global venture capital firm investing in visionary startups, offering guidance and industry disruption.

Investment Firm4
Precursor VenturesPrecursor VenturesSan Francisco, CA, USest. 2015Precursor VenturesSan Francisco, CA, US · est. 2015

Early-stage venture firm, Precursor Ventures, specializes in seed investing across various sectors since 2015.

Investment Firm11
Angiex
Angiex
Series B$32.9M142015Cambridge, MA, US
Board Member· Board

Recent news

CPG startup Keychain snags $30M to build in India, grow in the USTechCrunch · 2025

Leadership at Angiex

Paul JaminetPaul JaminetCo-Founder
Marty J DuvallMarty J DuvallCEO
Harold DvorakHarold DvorakCo-Founder
Peptilogics
Peptilogics
Series D$44.1M282013Pittsburgh, PA, US
Board Member· Board

Leadership at Peptilogics

Jonathan SteckbeckJonathan SteckbeckCo-Founder
Dietrich StephanDietrich StephanBoard Member
Ronald MontelaroRonald MontelaroCo-Founder

Similar to Peptilogics

20n Bio20n BioMalvern, PA, USPeptide Therapeuticsest. 202120n BioMalvern, PA, US · est. 2021

20n Bio, a VC-backed start-up in Malvern, PA, specializes in designing novel protein therapeutics.

Seed · $3.3M4
Lytica TherapeuticsLytica TherapeuticsCambridge, MA, USPeptides, Therapeuticsest. 2019Lytica TherapeuticsCambridge, MA, US · est. 2019

Lytica Therapeutics, Inc.: A biotech firm specializing in novel peptide therapeutics development.

Series A · $5.3M10
LactocoreLactocoreNewton, MA, USPeptide Therapeuticsest. 2018LactocoreNewton, MA, US · est. 2018

Novel peptide therapeutics firm, innovating safe solutions for psychiatric, metabolic diseases.

Pre-Seed · $3M32
Peptide LogicPeptide LogicSan Diego, CA, USPharmaceuticalsest. 2013Peptide LogicSan Diego, CA, US · est. 2013

Peptide Logic: A biopharmaceutical firm innovating peptide-antibody conjugates for pain therapy and more.

Seed · $2.9M7
Alloy Therapeutics
Alloy Therapeutics
Series D$128.3M1342017Waltham, MA, US
Board Member· Board

Leadership at Alloy Therapeutics

Alaa HalawaAlaa HalawaBoard Member
Errik AndersonErrik AndersonBoard Member

Similar to Alloy Therapeutics

OmniAbOmniAbEmeryville, CA, USAntibody Discoveryest. 2021OmniAbEmeryville, CA, US · est. 2021

OmniAb: Your pharmaceutical partner in discovering next-generation therapeutics through diverse antibody repertoires.

Public · $70M175
Allyx TherapeuticsAllyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4
Parallel BioParallel BioCambridge, MA, USDrug Discoveryest. 2021Parallel BioCambridge, MA, US · est. 2021

Parallel Bio: Human immune system platform for drug and vaccine testing.

Seed · $4.6M9
AltruBioAltruBioLos Altos, CA, USAntibody Therapeuticsest. 2000AltruBioLos Altos, CA, US · est. 2000

AltruBio, a global biotech firm, develops targeted antibody therapeutics for cancer and immune diseases.

Series A · $102.6M5

Fabian Hansen's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Fabian Hansen

Jason CammJason CammBoard Member · The Thiel FoundationPatrick SislianPatrick SislianCo-Founder · DetonTim HansenTim HansenBoard Member · Cinch